Spero Therapeutics (NASDAQ:SPRO) released its earnings results on Thursday. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.04, Zacks reports. The business had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $0.66 million. Spero Therapeutics had a negative net margin of 1,479.91% and a negative return on equity of 132.11%.
SPRO opened at $8.57 on Friday. The stock has a market cap of $156.79 million and a P/E ratio of -0.48. Spero Therapeutics has a twelve month low of $7.80 and a twelve month high of $19.00.
A number of analysts have recently commented on the stock. Zacks Investment Research raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 target price for the company in a research note on Friday, October 19th. Bank of America cut shares of Spero Therapeutics from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $19.00 to $9.00 in a research note on Tuesday, October 16th. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Sunday, September 30th. Finally, Cantor Fitzgerald set a $27.00 target price on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Thursday, September 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Spero Therapeutics has an average rating of “Buy” and a consensus target price of $21.58.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Recommended Story: Relative Strength Index
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.